New Frontiers in Treating Metastatic Cervical Cancer From Revolutionary Molecules to Clinical Therapies
                                                
                            
            
            
                
                                     ESGO eAcademy. Presenters F.                     10/23/21;                    346489                
                
                
                
                
            
         
                        
                            
                            Ignace Vergote
                                                    
                                     
                      
                         
                        
                            
                            Christian Marth
                                                    
                      
                         
                        
                            
                            Isabelle Ray-Coquard
                                                    
                      
                         
                        
                            
                            Mansoor Raza Mirza
                                                    
                      
                         
                        
                            
                            Domenica Lorusso
                                                    
                                                REGULAR CONTENT
                About this activity
            
        
        
        
        
        
        
         
        
        
                                    
                    Discussion Forum (0)
                
                                
        
    Chair: Ignace Vergote (Belgium)
15:00-15:05 Introduction by Ignace Vergote (Belgium)
15:05-15:20 Perspectives on current treatment landscape for r/m CC by Christian Marth (Austria), Ignace Vergote (Belgium)
15:20-15:35 Experts discuss future treatment modalities for r/m CC byIsabelle Ray-Coquard (France), Mansoor Raza Mirza (Denmark)
15:35-15:50 Can ADCs change r/m CC treatment landscape? by Domenica Lorusso (Italy), Ignace Vergote (Belgium)
15:50-16:00 Live Q&A
Technical Settings:
This live session is available on PC, Tablet and Smartphones. For the best viewing experience, a high-speed internet connection is required. If you have a problem accessing the live webinar, please contact the technical support team at support@multilearning.com.
        
        
        
        
        
        
        
        
        
                                    15:00-15:05 Introduction by Ignace Vergote (Belgium)
15:05-15:20 Perspectives on current treatment landscape for r/m CC by Christian Marth (Austria), Ignace Vergote (Belgium)
15:20-15:35 Experts discuss future treatment modalities for r/m CC byIsabelle Ray-Coquard (France), Mansoor Raza Mirza (Denmark)
15:35-15:50 Can ADCs change r/m CC treatment landscape? by Domenica Lorusso (Italy), Ignace Vergote (Belgium)
15:50-16:00 Live Q&A
Technical Settings:
This live session is available on PC, Tablet and Smartphones. For the best viewing experience, a high-speed internet connection is required. If you have a problem accessing the live webinar, please contact the technical support team at support@multilearning.com.
                        Code of conduct/disclaimer available in General Terms & Conditions
                    
                Trending Content
{{ help_message }}
    {{filter}}
                 
                             
        
 
                                     
                 
                 
                     
                     
                     
                                 
                     
                                 
                     
                     
                     
                                 
                     
                                 
                                 
                     
                     
                                 
                     
                                 
                     
                     
                                                     
                                                    